100777-49-9

Usage

Appearance

Colorless to pale yellow liquid This describes the physical appearance of the compound in its pure form.

Molecular weight

253.25 g/mol This is the mass of one mole of the compound, which helps determine its molar concentration in various applications.

Uses as a coupling agent

Synthesis of dyes 2-(3-methoxy-4-nitrophenylthio)ethanol is used to join two chemical groups together, specifically in the production of dyes.

Uses as a building block

Production of pharmaceuticals and other organic compounds 2-(3-methoxy-4-nitrophenylthio)ethanol serves as a fundamental component in the creation of various pharmaceuticals and organic compounds.

Application as a reagent

Organic synthesis 2-(3-methoxy-4-nitrophenylthio)ethanol is used as a reactant in organic synthesis, aiding in the formation of new chemical bonds and structures.
7. Application in the manufacture of fragrances and flavorings The compound is used as a starting material or intermediate in the production of various fragrances and flavorings.

Potential applications

Medicine, agriculture, and industry Due to its diverse chemical properties and reactivity, the compound has potential uses in a wide range of fields.

Hazardous if not properly managed

Caution required Handling and disposal of 2-(3-methoxy-4-nitrophenylthio)ethanol should be done with care, as it may pose risks to human health and the environment if not managed correctly.

Upstream product

• 448-19-1 4-fluoro-2-methoxy-1-nitrobenzene 
• 623-51-8 ethyl 2-sulfanylacetate 
• 60-24-2 2-hydroxyethanethiol 
• 6627-53-8 1-chloro-3-methoxy-4-nitrobenzene 

Relevant academic research and scientific papers

Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants

In order to explore novel ALK and ROS1 dual inhibitors capable of overcoming crizotinib-resistant mutants, two series of 2,4-diarylaminopyrimidine derivatives were designed, synthesized and evaluated for their in vitro cytotoxic activity. In this work, we retained the 2,4-diarylaminopyrimidine scaffold and derivatize the DAAP scaffold with sulfonyl and acrylamide moieties to extend the structure–activity relationship (SAR) study. To our delight, some compounds exhibited excellent inhibitory activity with a double-digit nanomolar level in MTT assay. Four compounds were selected for enzymic assays further, the results led to the identification of a potent ALK and ROS1 dual inhibitor X-17, with IC50 values of 3.7 nM, 2.3 nM, 8.9 nM and 1.9 nM against ALK, ALKL1196M, ALKG1202R and ROS1, respectively. Ultimately, the molecular docking studies on X-17 clearly disclosed reasonable and optimal binding interactions with ALK.

Design, synthesis and biological evaluation of novel pteridinone derivatives possessing a sulfonyl moiety as potent dual inhibitors of PLK1 and BRD4

The simultaneous inhibition of PLK1 and BRD4 by a single molecule could lead to the development of an effective therapeutic strategy for a variety of diseases in which PLK1 and BRD4 are implicated. Herein, two series of novel pteridinone derivatives possessing a sulfonyl moiety were designed, synthesized and evaluated for their biological activity. Most compounds exhibited moderate to excellent cytotoxic activity against HCT116, PC3 and BT474 cell lines. Among them, the most promising compound B2 showed high antiproliferative effects on the three cell lines with IC50 values of 0.30 μM, 1.82 μM and 1.69 μM, respectively. In the enzymatic assay, B2 was identified as a potent PLK1 and BRD4 dual inhibitor (PLK1 IC50 = 6.3 nM, BRD4 IC50 = 179 nM). Further explorations in bioactivity were conducted to clarify the anticancer mechanism of compound B2. The results showed that compound B2 obviously inhibited the proliferation of HCT116 cell lines, induced a great decrease in the mitochondrial membrane potential leading to apoptosis of HCT116 cells and arrested the G2 phase of HCT116 cells.

METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

2,4-diarylaminopyrimidine derivative as well as preparation method and application thereof

The invention relates to a 2,4-diarylaminopyrimidine derivative shown as a general formula I and optical isomers thereof, pharmaceutically acceptable salts, solvates or prodrugs, as well as preparation methods thereof and a pharmaceutical composition taking the compound of the general formula I as an active ingredient. In the formula, substituent groups R1, R2, R3, R4, R5, R6 and X have meanings given in the description. The invention further relates to a compound of the general formula I with strong ALK and ROS1 kinase inhibition effects, and further relates to application of the compounds and optical isomers and pharmaceutically acceptable salts thereof in preparation of medicines for treating and/or preventing diseases caused by abnormal expressions of ALK and ROS1, particularly application in preparation of medicines for treating and/or preventing cancers. The structural formula is as shown in the description.

SULFOXIDE DERIVATIVES FOR THE TREATMENT OF TUMORS

Sulfoxide derivatives of the formula Ia to Im as described, and pharmaceutically usable salts, solvates, enantiomers, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for the treatment of tumours.